Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy
IntroductionDecline in kidney function due to renal fibrosis is a potential side effect in patients with neuroendocrine neoplasm (NEN) undergoing Peptide Receptor Radionuclide Therapy (PRRT). We aimed to investigate the potential of circulating fibrosis markers reflecting formation and degradation o...
Saved in:
Main Authors: | Tobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, Federica Genovese, Morten Karsdal, Anne Kirstine Arveschoug, Henning Grønbæk, Gitte Dam |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-06-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1495369/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report
by: Ryosuke Umino, et al.
Published: (2024-02-01) -
NEUROENDOCRINE TUMORS OF THE CERVIX
by: K. V. Safronova, et al.
Published: (2020-10-01) -
Mixed neuroendocrine–non-neuroendocrine neoplasm of the ampulla of Vater: a case report
by: Kenjiro Date, et al.
Published: (2023-06-01) -
A case of small cell neuroendocrine carcinoma of the ampulla of Vater
by: Hiroharu Ito, et al.
Published: (2020-06-01) -
Non-invasive of liver fibrosis diagnostics: the role of serum markers
by: A. F. Sheptulina, et al.
Published: (2015-05-01)